DUE DILIGENCE REPORT: Anavex Life Sciences Completes Enrollment for Clinical Phase 2a - BrokerBank Securities

Oct 06, 2015, 13:45 ET from BrokerBank Securities, Inc.

NEW YORK, Oct. 6, 2015 /PRNewswire/ -- Anavex Life Sciences Corp. (OTCQX: AVXL) shares closed at $1.90 yesterday, up 18.44%. Trading volume exceeded the 30 day average by a factor of three. The AVXL share price has been on a significant rise since July.

Our due diligence will show investors in Anavex Life Sciences Corp. information about the company and its products to make their investment choices. Get our due diligence report at the link below.

http://bit.ly/-AVXL_Due_Diligence_Report

Copy and paste to browser may be required.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a biopharmaceutical company dedicated to the development of novel drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer.  Anavex's lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer's disease.  Initial positive data was presented at AAIC 2015 and full PART A data is expected by year end.

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.  

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. This release and report was prepared for informational purposes only.  Affiliated parties involved with producing and issuing this release have not been compensated in any form by any source.  A full disclaimer can be found by viewing due diligence. We are only human and may make mistakes. If you notice any errors or omissions, please notify us below.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.



RELATED LINKS

http://www.brokerbanksecurities.com